| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M A Nauc. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta diabetologica. vol 35. issue 3. 1999-02-05. PMID:9840447. |
in addition, glp-1 also lowers glucagon concentrations, slows gastric emptying, stimulates (pro)insulin biosynthesis, and reduces food intake upon intracerebroventricular administration in animals. |
1999-02-05 |
2023-08-12 |
Not clear |
| M A Nauc. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta diabetologica. vol 35. issue 3. 1999-02-05. PMID:9840447. |
in contrast, glp-1 glucose-dependently stimulates insulin secretion in type-2 diabetic patients and exogenous administration of glp-1 ([7-37] or [7-36 amide]) in doses elevating plasma concentrations to approximately three to four times physiological postprandial levels fully normalizes fasting hyperglycaemia and reduces postprandial glycaemic increments. |
1999-02-05 |
2023-08-12 |
Not clear |
| J van Delft, O Uttenthal, C Koch, M Ghiglion. Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose. Metabolism: clinical and experimental. vol 48. issue 1. 1999-02-04. PMID:9920143. |
the physiological action of endogenous active forms of glucagon-like peptide-1 (glp-1) on the insulin response to intragastric glucose was studied in conscious male wistar rats by immunoblockade with two monoclonal antibodies directed against different epitopes of glp-1(7-36)amide. |
1999-02-04 |
2023-08-12 |
rat |
| J van Delft, O Uttenthal, C Koch, M Ghiglion. Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose. Metabolism: clinical and experimental. vol 48. issue 1. 1999-02-04. PMID:9920143. |
the action of glp-1 appears particularly important for the early insulin response to ingested glucose, and the unexpected effect of the antibodies on the glucose response may point to a net promoting effect of glp-1 on intestinal glucose absorption. |
1999-02-04 |
2023-08-12 |
rat |
| E J Freyse, S Knospe, T Becher, O El Hag, B Göke, U Fische. Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. Metabolism: clinical and experimental. vol 48. issue 1. 1999-02-04. PMID:9920158. |
the animals were under normoglycemic control by glucose-controlled insulin infusion (gcii) during the night before and during glp-1 administration. |
1999-02-04 |
2023-08-12 |
Not clear |
| E J Freyse, S Knospe, T Becher, O El Hag, B Göke, U Fische. Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. Metabolism: clinical and experimental. vol 48. issue 1. 1999-02-04. PMID:9920158. |
in addition to the insulin infusion rates required to maintain normoglycemia, hormones, metabolites, and the turnover rates for glucose (6-3h-glucose), alanine (u-14c-alanine), and urea (15n2-urea) were measured during the final 2 hours of glp-1 administration. |
1999-02-04 |
2023-08-12 |
Not clear |
| M A Nauck, I Weber, I Bach, S Richter, C Orskov, J J Holst, W Schmiege. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabetic medicine : a journal of the British Diabetic Association. vol 15. issue 11. 1999-02-01. PMID:9827848. |
glp-1 infusions stimulated insulin secretion approximately 3-fold (insulin peak 168+/-32 and 156+/-47 pmol l(-1), p<0.0001 vs basal; c-peptide peak 2.32+/-0.28 and 2.34+/-0.43 nmol l(-1), p<0.0001, respectively, with glp-1 [7-36 amide] and [7-37]). |
1999-02-01 |
2023-08-12 |
human |
| M A Nauck, I Weber, I Bach, S Richter, C Orskov, J J Holst, W Schmiege. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabetic medicine : a journal of the British Diabetic Association. vol 15. issue 11. 1999-02-01. PMID:9827848. |
there were no significant differences between glp-1 [7-36 amide] and [7-37] (glucose, p=0.99; insulin, p=0.99; c-peptide, p=0.99). |
1999-02-01 |
2023-08-12 |
human |
| U Ritzel, U Leonhardt, M Ottleben, A Rühmann, K Eckart, J Spiess, G Ramador. A synthetic glucagon-like peptide-1 analog with improved plasma stability. The Journal of endocrinology. vol 159. issue 1. 1999-01-29. PMID:9795346. |
injection of [ser]glp-1(7-36)amide and glucose in rats induced a twofold higher increase in plasma insulin levels than unmodified glp-1(7-36)amide with glucose and a fivefold higher increase than glucose alone. |
1999-01-29 |
2023-08-12 |
human |
| U Ritzel, U Leonhardt, M Ottleben, A Rühmann, K Eckart, J Spiess, G Ramador. A synthetic glucagon-like peptide-1 analog with improved plasma stability. The Journal of endocrinology. vol 159. issue 1. 1999-01-29. PMID:9795346. |
[ser]glp-1(7-36)amide induced a 1.5-fold higher increase in plasma insulin than glp-1(7-36)amide when given 1 h before i.v. |
1999-01-29 |
2023-08-12 |
human |
| C M Edwards, J F Todd, M A Ghatei, S R Bloo. Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clinical science (London, England : 1979). vol 95. issue 6. 1999-01-26. PMID:9831697. |
1.glucagon-like peptide-1 (7-36) amide (glp-1) is a gut hormone released postprandially that stimulates insulin secretion, suppresses glucagon secretion and delays gastric emptying. |
1999-01-26 |
2023-08-12 |
human |
| J F Todd, C M Edwards, M A Ghatei, H M Mather, S R Bloo. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clinical science (London, England : 1979). vol 95. issue 3. 1999-01-14. PMID:9730852. |
the plasma insulin excursions were significantly higher with glp-1 compared with saline over the initial postprandial 30 min, the time period during which the glp-1 concentration was considerably elevated. |
1999-01-14 |
2023-08-12 |
Not clear |
| J F Todd, C M Edwards, M A Ghatei, H M Mather, S R Bloo. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clinical science (London, England : 1979). vol 95. issue 3. 1999-01-14. PMID:9730852. |
the beneficial effects of glp-1 on plasma glucose, insulin and glucagon concentrations were fully maintained for the 3-week treatment period. |
1999-01-14 |
2023-08-12 |
Not clear |
| J F Todd, C M Edwards, M A Ghatei, H M Mather, S R Bloo. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clinical science (London, England : 1979). vol 95. issue 3. 1999-01-14. PMID:9730852. |
glp-1 improves glycaemic control partially by restoring the first-phase insulin response and suppressing glucagon and is a potential treatment for type 2 diabetes. |
1999-01-14 |
2023-08-12 |
Not clear |
| M Toft-Nielsen, S Madsbad, J J Hols. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia. vol 41. issue 10. 1999-01-14. PMID:9794105. |
with glp-1, infusion of a total of 33.4 +/- 1.3 g glucose was required to obtain plasma glucose concentrations similar to those obtained by glucose infusion alone; with low gip, 28.0 +/- 1.2 g and with high gip 38.4 +/- 3.5 g. insulin concentrations increased 10-fold with glp-1 compared with i.v. |
1999-01-14 |
2023-08-12 |
human |
| F P O'Harte, Y H Abdel-Wahab, J M Conlon, P R Flat. Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells. Diabetologia. vol 41. issue 10. 1999-01-14. PMID:9794106. |
glucagon-like peptide-1(7-36)amide(truncated glp-1, tglp-1) is a potent insulin releasing hormone of the enteroinsular axis. |
1999-01-14 |
2023-08-12 |
mouse |
| G Rosselin, V Leclercq-Meyer, C Boissart, M Pessah, W J Malaiss. GLP-1 receptors in golden Syrian hamster islets: identification and functional characterization. Endocrine. vol 8. issue 3. 1998-11-24. PMID:9741838. |
in the isolated perfused pancreas of golden syrian hamsters, a rise in d-glucose concentration from 3.3 to 8.3 mm caused a biphasic stimulation of insulin release, which was further increased by either glp-1 or glucagon (10(-9)m each). |
1998-11-24 |
2023-08-12 |
human |
| G Rosselin, V Leclercq-Meyer, C Boissart, M Pessah, W J Malaiss. GLP-1 receptors in golden Syrian hamster islets: identification and functional characterization. Endocrine. vol 8. issue 3. 1998-11-24. PMID:9741838. |
the enhancing action of glp-1 on glucose-stimulated insulin secretion was much more marked than that of glucagon. |
1998-11-24 |
2023-08-12 |
human |
| S P Massimino, M I McBurney, C J Field, A B Thomson, M Keelan, M G Hayek, G D Sunvol. Fermentable dietary fiber increases GLP-1 secretion and improves glucose homeostasis despite increased intestinal glucose transport capacity in healthy dogs. The Journal of nutrition. vol 128. issue 10. 1998-11-13. PMID:9772150. |
food was withheld for 16 h before an oral glucose tolerance test was conducted supplying 2 g of glucose/kg body wt, and peripheral blood was collected via a hind-leg catheter at 0, 15, 30, 45, 60, 90 and 120 min for plasma glucose, insulin and glucagon-like peptide-1(7-36)nh2 (glp-1) analyses. |
1998-11-13 |
2023-08-12 |
rat |
| S P Massimino, M I McBurney, C J Field, A B Thomson, M Keelan, M G Hayek, G D Sunvol. Fermentable dietary fiber increases GLP-1 secretion and improves glucose homeostasis despite increased intestinal glucose transport capacity in healthy dogs. The Journal of nutrition. vol 128. issue 10. 1998-11-13. PMID:9772150. |
ileal proglucagon mrna, intestinal (glp-1) concentrations and the integrated area under the curves (auc) for plasma glp-1 and insulin were greater and plasma glucose auc was reduced when dogs were fed the hff diet compared to the lff diet (p < 0.05). |
1998-11-13 |
2023-08-12 |
rat |